Vishwesh Shah's questions to Aurinia Pharmaceuticals Inc (AUPH) leadership • Q2 2025
Question
Vishwesh Shah inquired about the strategic potential for Aratinircept, including value-driving indications and potential dosing based on recent study data. He also asked about the impact of updated ACR guidelines on Lupkynis adoption and the prescriber mix between rheumatology and nephrology.
Answer
President and CEO Peter Greenleaf highlighted that Aratinircept could target over 20 B-cell mediated diseases but declined to specify indications for competitive reasons. Chief Medical Officer Dr. Greg Keenan added that Phase 1 data supports a Q4-week dosing schedule. Regarding Lupkynis, Greenleaf confirmed the ACR guidelines have helped drive a notable increase in prescribing from rheumatologists and in hospital settings.